Abstract
Trials reported at the 2023 ESMO Congress showed significant improvements in median overall survival (OS)-for the first time ever-in patients newly diagnosed with advanced or metastatic urothelial carcinoma who received combination therapies instead of standard chemotherapy. In one trial, median OS nearly doubled in patients who received the antibody-drug conjugate enfortumab vedotin combined with the PD-1 inhibitor pembrolizumab compared with those who received standard chemotherapy-31.5 months versus 16.1 months. In a second trial, the combination of the PD-1 inhibitor nivolumab and standard chemotherapy bested standard chemotherapy alone.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
